Make the Diagnosis

Progressive, pruritic eruption of firm, skin-colored papules

Courtesy Rachel Fayne, BA, Dr. Yumeng Li, Dr. Fabrizio Galimberti, and Dr. Brian Morrison
A 72-year-old Hispanic male presented with a year-long history of a progressive, pruritic eruption consisting of firm, skin-colored papules on the head and neck that spread to the upper back, chest, proximal arms, and abdomen. He had joint swelling and pain. A biopsy was performed to confirm the diagnosis. Upon treatment with intravenous immunoglobulin (IVIg), his condition improved. After his fifth IVIg treatment, he developed smooth pink papules over the extensor elbows, knees, and feet. These lesions were biopsied as well. Serum protein electrophoresis demonstrated biclonal IgG with lambda and monoclonal IgA with kappa specificity.

Make the diagnosis:

Scleromyxedema

Scleromyxedema with concurrent erythema elevatum diutinum

Amyloidosis

Scleroderma with concurrent erythema elevatum diutinum

Scleromyxedema, or generalized lichen myxedematosus, is a primary cutaneous mucinosis with unknown pathogenesis characterized by generalized firm, skin-colored papules and is commonly associated with an underlying monoclonal gammopathy (usually Ig-gamma paraproteinemia).

Courtesy Rachel Fayne, BA, Dr. Yumeng Li, Dr. Fabrizio Galimberti, and Dr. Brian Morrison

Scleromyxedema may have associated internal involvement, including neurologic, gastrointestinal, pulmonary, renal, cardiovascular, ophthalmological, or musculoskeletal. Histopathology demonstrates mucin in the dermis seen with Alcian blue staining, proliferation of fibroblasts, and increased collagen deposition.

The condition is chronic and progressive. Intravenous immunoglobulin is considered first-line treatment. Thalidomide and corticosteroids have been reported to also be efficacious.

Erythema elevatum diutinum (EED) is a small-vessel vasculitis that presents with asymptomatic, symmetrical nodules or plaques on extensor surfaces. It is associated with hematologic disorders, including IgA monoclonal gammopathy, as well as myeloproliferative disorders, leukemia, infections, and inflammatory bowel disease. Although its pathophysiology is not well understood, vascular immune complex deposition, repetitive inflammation, and subsequent fibrosis may play a role. On histology, there is leukocytoclastic vasculitis with polymorphonuclear cell infiltrate and fibrin deposition in the superficial and mid-dermis and onion-skin fibrosis.

EED often self-resolves within 5-10 years, although it can become chronic and recurrent. Dapsone, niacinamide, antimalarials, NSAIDs, tetracyclines, corticosteroids, colchicine, and plasmapheresis are reported treatments. This patient’s EED was recalcitrant to prednisone and responded to colchicine.

Scleromyxedema and EED are both rare, distinct cutaneous entities associated with different underlying paraproteinemias and to the best of our knowledge, have not been previously reported to coexist in a single patient.

Dr. Donna Bilu Martin, a dermatologist in private practice in Aventura, Fla.

Dr. Donna Bilu Martin

This case and the photos were submitted by Rachel Fayne, BA; Yumeng Li, MD, MS; Fabrizio Galimberti, MD, PhD; and Brian Morrison, MD, of the department of dermatology and cutaneous surgery at the University of Miami.

Dr. Bilu Martin is a board-certified dermatologist in private practice at Premier Dermatology, MD, in Aventura, Fla. More diagnostic cases are available at mdedge.com/dermatology. To submit a case for possible publication, send an email to dermnews@mdedge.com.

Recommended Reading

Violaceous papules on calf & foot
MDedge Dermatology
Rapid improvement seen with nemolizumab for prurigo nodularis in phase 2b study
MDedge Dermatology
Don’t leave dermatomyositis to the rheumatologists
MDedge Dermatology
Asymptomatic hypopigmented macules and patches
MDedge Dermatology
Hot tips on uncovering the causes of sweating
MDedge Dermatology
Sweaty patient? Treatments require patient education
MDedge Dermatology
Bezafibrate beats placebo in pruritus of chronic cholestasis: The FITCH trial
MDedge Dermatology
Dermatologists: Beware the ‘insulin ball’
MDedge Dermatology
Apremilast for Behçet’s oral ulcers: Benefits maintained at 64 weeks
MDedge Dermatology
Dupilumab could be treatment option for chronic keloids
MDedge Dermatology